Values as of: 2024-11-13
COMMON STOCK | Medical Devices |
Last Closing
USD 82.54Change
-0.88 (-1.05)%Market Cap
USD 11.01BVolume
0.96MAnalyst Target
USD 60.85Verdict
Verdict
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Company Website : https://www.globusmedical.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ABT | Abbott Laboratories |
-0.70 (-0.60%) |
USD 201.96B |
| MDT | Medtronic PLC |
-0.33 (-0.37%) |
USD 115.52B |
| STE | STERIS plc |
-0.46 (-0.21%) |
USD 21.88B |
| ZBH | Zimmer Biomet Holdings Inc |
+0.03 (+0.03%) |
USD 21.28B |
| SNN | Smith & Nephew SNATS Inc |
+0.04 (+0.16%) |
USD 10.91B |
| BIO | Bio-Rad Laboratories Inc |
-1.33 (-0.36%) |
USD 10.06B |
| PEN | Penumbra Inc |
-0.17 (-0.07%) |
USD 9.07B |
| GKOS | Glaukos Corp |
-0.38 (-0.26%) |
USD 7.82B |
| INSP | Inspire Medical Systems Inc |
-8.57 (-4.49%) |
USD 6.34B |
| ITGR | Integer Holdings Corp |
+0.67 (+0.49%) |
USD 4.59B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| CIB0:XETRA | VanEck Bionic Engineering.. | 3.50 % | 0.00 % |
+0.12 (+0.24%) |
USD 4.90M |
| CYBG:LSE | VanEck Bionic Engineering.. | 3.35 % | 0.00 % |
+0.04 (+0.24%) |
N/A |
| EASI | 2.82 % | 0.75 % |
N/A |
N/A | |
| XHE | SPDR® S&P Health Care Eq.. | 2.03 % | 0.35 % |
-1.55 (0.24%) |
USD 0.22B |
| GGEM:CA | 0.00 % | 0.00 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 54.89% | 87% | B+ | 94% | A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 54.89% | 87% | B+ | 93% | A | ||
| Trailing 12 Months | |||||||
| Capital Gain | 80.18% | 83% | B | 94% | A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 80.18% | 83% | B | 94% | A | ||
| Trailing 5 Years | |||||||
| Capital Gain | 50.24% | 70% | C- | 70% | C- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 50.24% | 65% | D | 64% | D | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 7.57% | 50% | F | 60% | D- | ||
| Dividend Return | 7.57% | 50% | F | 53% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 27.71% | 73% | C | 39% | F | ||
| Risk Adjusted Return | 27.32% | 60% | D- | 44% | F | ||
| Market Capitalization | 11.01B | 85% | B | 87% | B+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
